- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02602496
Promoting Gastrointestinal Health and Reducing Subclinical Inflammation in Obese Individuals
May 22, 2019 updated by: Devin Rose, University of Nebraska Lincoln
Promoting Gastrointestinal Health and Reducing Subclinical Inflammation in Obese Individuals Through Intake of Whole Wheat Products in Comparison With Fruits and Vegetables
This study evaluates the impact of increased intake of fruits and vegetables and whole grains on markers of inflammation and gut microbial composition.
The treatment groups are 3 servings of whole grain per day; 5 servings of fruits and vegetables per day; and a control (3 servings of refined grains per day provided).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Literature data suggests that fruits and vegetables and whole grains containing dietary fiber and other nutrients are important for maintaining beneficial microbes in the gut.
The presence of beneficial microbes in the gut may mediate the subclinical inflammation experienced in metabolic disease.
In this project, overweight or obese participants with low intakes of fruits and vegetables or whole grains will increase their intake of these foods to recommended levels.
Changes in markers of inflammation and gut microbiota composition will be determined to assess and compare the potential impact of these foods on metabolic disease.
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68588
- Food Innovation Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Obese or overweight men or women (body mass index, BMI, ≥25 kg/m2)
- Free of known gastrointestinal disease
- No supplements use (excluding multivitamin)
- Participate in less than 1 h of exercise per week
- Have not taken antibiotics in the last six months
Exclusion Criteria:
- Men and women with fruits and vegetable intake exceeding 2 servings/day
- Men and women with whole grain intakes exceeding 1 serving/day
- Pregnant
- Do not fit the inclusion criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Control
3 servings of refined grains per day.
|
3 servings of refined grain
|
Experimental: Fruits and Vegetables
5 servings of fruits and vegetable per day.
|
5 servings of fruits or vegetables
|
Experimental: Whole Grain
3 servings of whole grains per day.
|
3 servings of whole grain
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Interleukin-6 (Value at Week 8 Minus Value at Week 0)
Time Frame: 8 weeks
|
Plasma samples collected from participants at the beginning (week 0) and end of the study (week 8) will be analyzed for interleukin-6 concentrations using an enzyme linked immunosorbent assay.
Changes in the concentrations of these inflammatory markers will be determined from week 0 to week 8.
|
8 weeks
|
Change in Tumor Necrosis Factor-α (Value at Week 8 Minus Value at Week 0)
Time Frame: 8 weeks
|
Plasma samples collected from participants at the beginning (week 0) and end of the study (week 8) will be analyzed for tumor necrosis factor-α concentrations using an enzyme linked immunosorbent assay.
Changes in the concentrations of these inflammatory markers will be determined from week 0 to week 8.
|
8 weeks
|
Change in High Sensitivity C-reactive Protein (Value at Week 8 Minus Value at Week 0)
Time Frame: 8 weeks
|
Plasma samples collected from participants at the beginning (week 0) and end of the study (week 8) will be analyzed for high sensitivity C-reactive protein concentrations using an enzyme linked immunosorbent assay.
Changes in the concentrations of these inflammatory markers will be determined from week 0 to week 8.
|
8 weeks
|
Change in Lipopolysaccharide Binding Protein (Value at Week 8 Minus Value at Week 0)
Time Frame: 8 weeks
|
Plasma samples collected from participants at the beginning (week 0) and end of the study (week 8) will be analyzed for lipopolysaccharide binding protein concentrations using an enzyme linked immunosorbent assay.
Changes in the concentrations of these inflammatory markers will be determined from week 0 to week 8.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Gut Microbiota Shannon's Alpha Diversity (Value at Week 8 Minus Value at Week 0)
Time Frame: 8 weeks
|
The Shannon Diversity Index is a quantitative measure that reflects how many different bacterial species there are in a sample.
The greater the index, the more diverse the gut microbiota.
A negative change indicates a decrease in diversity and a positive change indicates an increase in diversity.
|
8 weeks
|
Change in Fecal Short Chain Fatty Acids (Value at Week 8 Minus Value at Week 0)
Time Frame: 8 weeks
|
Short-chain fatty acids (SCFAs) are the end products of fermentation of dietary fibers by the anaerobic intestinal microbiota.
SCFAs have been shown to exert multiple beneficial effects on mammalian energy metabolism.
|
8 weeks
|
Change in Branched Chain Fatty Acids (Value at Week 8 Minus Value at Week 0)
Time Frame: 8 weeks
|
Branched chain fatty acids (BCFA) are mostly saturated fatty acids (SFA) with one or more methyl branches on the carbon chain.
BCFAs were extracted from stool samples and measured using gas chromatography.
|
8 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Body Mass Index (Value at Week 8 Minus Value at Week 0)
Time Frame: 8 weeks
|
Body mass index will be measured on participants at the beginning (week 0) and end of the study (week 8).
Changes in body mass index will be determined.
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Devin J Rose, PhD, University of Nebraska
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2015
Primary Completion (Actual)
June 1, 2017
Study Completion (Actual)
July 1, 2017
Study Registration Dates
First Submitted
November 4, 2015
First Submitted That Met QC Criteria
November 9, 2015
First Posted (Estimate)
November 11, 2015
Study Record Updates
Last Update Posted (Actual)
June 5, 2019
Last Update Submitted That Met QC Criteria
May 22, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UNebraskaLincolnFDST1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Control
-
Claudia M. WittCompleted
-
University of California, San FranciscoWithdrawn
-
Queen's University, BelfastPublic Health Agency, Health and Social Care Research and Development; Tiny...Completed
-
National Taiwan University HospitalEnrolling by invitationCognitive Function | Atrial Fibrillation, PersistentTaiwan
-
Takeshi MorimotoUniversity of the RyukyusActive, not recruitingCoronary Artery Disease | Hypertension | Type 2 Diabetes | DyslipidemiaJapan
-
Johnson & Johnson Vision Care, Inc.TerminatedRefractive Error CorrectionUnited States
-
Universidad Nacional de Educación a DistanciaMinisterio de Economía y Competitividad, SpainUnknownChronic Pain | FibromyalgiaSpain
-
University of California, Los AngelesThe National Council on Aging; City of Los Angeles Department of Aging; Los Angeles...Completed
-
Vanderbilt University Medical CenterCompleted
-
University Hospital, LilleCompleted